← FDA DRUG APPROVALS

FDA ANDA · ANDA090070

DIVALPROEX SODIUM

Sponsor: REDDYS

APPLICATION
ANDA090070
TYPE
ANDA
ORIGINAL APPROVAL
2012-03-12
LATEST ACTION
2024-07-10
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

DIVALPROEX SODIUMPrescription
DIVALPROEX SODIUM EQ 500MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL

Approval history

2024-07-10Labeling · Supplement 25 · standardAP
2023-06-08Labeling · Supplement 22 · standardAP
2023-06-08Labeling · Supplement 20 · standardAP
2023-06-08Labeling · Supplement 23 · standardAP
2020-02-20Labeling · Supplement 18 · standardAP
2020-02-20Labeling · Supplement 16 · standardAP
2020-02-20Labeling · Supplement 14 · standardAP
2020-02-20Labeling · Supplement 19 · standardAP
2020-02-20Labeling · Supplement 17 · standardAP
2020-02-20Labeling · Supplement 15 · standardAP
2020-02-20Labeling · Supplement 13 · standardAP
2016-01-04Labeling · Supplement 8 · standardAP
2016-01-04Labeling · Supplement 6 · standardAP
2016-01-04Labeling · Supplement 10 · standardAP
2016-01-04Labeling · Supplement 9 · standardAP
2016-01-04Labeling · Supplement 7 · standardAP
2014-11-20Labeling · Supplement 4 · standardAP
2014-11-20Labeling · Supplement 5 · standardAP
2014-11-20Labeling · Supplement 1 · standardAP
2012-03-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →